← back to search

Ming Gao

Guangzhou Eighth People's Hospital · CN
Area of research
Endocrinology, Diabetes and Metabolism · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Thyroid Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Radiomics and Machine Learning in Medical Imaging, and Lung Cancer Research Studies.
h-index
19
citations
1,485
works
149
NIH funding
primary concept
email

Recent publications

Suppressing Ralstonia solanacearum and Bacterial Antibiotic Resistance Genes in Tomato Rhizosphere Soil through Companion Planting with Basil or Cilantro
Agronomy 2024cited by 6position: middledoi
Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Clinical Cancer Research 2023cited by 36position: lastdoi
Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Clinical Cancer Research 2021cited by 112position: lastdoi
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Clinical Cancer Research 2021cited by 42position: lastdoi
Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.
Journal of Clinical Oncology 2021cited by 2position: middledoi
265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
Annals of Oncology 2020cited by 10position: middledoi
LBA88 Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
Annals of Oncology 2020cited by 8position: middledoi
421P A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Annals of Oncology 2020cited by 2position: firstdoi
Long-term liraglutide ameliorates nigrostriatal impairment via regulating AMPK/PGC-1a signaling in diabetic mice
Brain Research 2019cited by 29position: middledoi
Neoadjuvant dose‐modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study
Oral Diseases 2019cited by 9position: middledoi
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Thyroid 2018cited by 112position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Zhuming Guo · Nanfang Hospital7 papers (2018–2023)Xiangqian Zheng · Center for Cancer Research6 papers (2020–2023)Jianwu Qin · Zhengzhou University6 papers (2020–2023)Zhengang Xu · Nanchang University5 papers (2020–2023)Ruochuan Cheng · Jilin University5 papers (2020–2023) · 5 papers (2018–2023)Ying Cheng · Changzhi University5 papers (2020–2023)Yihebali Chi · Chinese Academy of Medical Sciences & Peking Union Medical College5 papers (2018–2023)Minghua Ge · Wenzhou Medical University4 papers (2020–2021)Minghua Ge · Dalian Medical University4 papers (2019–2023)Qinghai Ji · Fudan University3 papers (2018–2021)Y. Zhang · Medical College of Wisconsin3 papers (2020–2020) · 3 papers (2020–2023)Yuan Zhang · Wenzhou Medical University3 papers (2018–2021)Dapeng Li · Jiangsu University3 papers (2021–2023)Qiang Li · Nanjing Medical University3 papers (2018–2021)Xiaohong Chen · Guangzhou Medical University3 papers (2021–2023)Jiewu Zhang · Harbin Medical University3 papers (2021–2023) · 2 papers (2020–2020) · 2 papers (2020–2021)